JP6902045B2 - ピリミジンおよびそのバリアント、ならびにそのための使用 - Google Patents
ピリミジンおよびそのバリアント、ならびにそのための使用 Download PDFInfo
- Publication number
- JP6902045B2 JP6902045B2 JP2018549444A JP2018549444A JP6902045B2 JP 6902045 B2 JP6902045 B2 JP 6902045B2 JP 2018549444 A JP2018549444 A JP 2018549444A JP 2018549444 A JP2018549444 A JP 2018549444A JP 6902045 B2 JP6902045 B2 JP 6902045B2
- Authority
- JP
- Japan
- Prior art keywords
- compound
- mmol
- mixture
- formula
- added
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 0 CC(C)c(cc(cc1)OC)c1Sc1cnc(N)nc1N* Chemical compound CC(C)c(cc(cc1)OC)c1Sc1cnc(N)nc1N* 0.000 description 3
- CTJOZPFWVUXWIX-UHFFFAOYSA-N CC(C)c(c(Sc1c(N)nc(N)nc1)c1)cc(OC)c1C#C[Si](C)(C)C Chemical compound CC(C)c(c(Sc1c(N)nc(N)nc1)c1)cc(OC)c1C#C[Si](C)(C)C CTJOZPFWVUXWIX-UHFFFAOYSA-N 0.000 description 1
- HQGQGVOZAWVQAN-UHFFFAOYSA-N CC(C)c(c(Sc1c[nH]nc1N)c1)cc(OC)c1C#C Chemical compound CC(C)c(c(Sc1c[nH]nc1N)c1)cc(OC)c1C#C HQGQGVOZAWVQAN-UHFFFAOYSA-N 0.000 description 1
- DIVZAOOBIBOFQE-UHFFFAOYSA-N CC(C)c(c(Sc1cnc(N)nc1N)c1)cc(OC)c1Br Chemical compound CC(C)c(c(Sc1cnc(N)nc1N)c1)cc(OC)c1Br DIVZAOOBIBOFQE-UHFFFAOYSA-N 0.000 description 1
- DLRDJUCQPGETIR-UHFFFAOYSA-N CC(C)c(cc(c(I)c1)OC)c1Sc1c[nH]nc1N Chemical compound CC(C)c(cc(c(I)c1)OC)c1Sc1c[nH]nc1N DLRDJUCQPGETIR-UHFFFAOYSA-N 0.000 description 1
- CNLREBAATZJHJW-UHFFFAOYSA-N CC(C)c(cc(c(OC)c1)OC)c1S(c1cnc(N)nc1N)=O Chemical compound CC(C)c(cc(c(OC)c1)OC)c1S(c1cnc(N)nc1N)=O CNLREBAATZJHJW-UHFFFAOYSA-N 0.000 description 1
- IWPHXSVEEYGWPM-UHFFFAOYSA-N CC(C)c(nc(c(I)c1)OC)c1Oc1c(N)nc(N)nc1 Chemical compound CC(C)c(nc(c(I)c1)OC)c1Oc1c(N)nc(N)nc1 IWPHXSVEEYGWPM-UHFFFAOYSA-N 0.000 description 1
- ZGDYNXRQVWHHOF-UHFFFAOYSA-N CCc(c(Sc1cnc(N)nc1N)c1)cc(OC)c1S(C)(=O)=O Chemical compound CCc(c(Sc1cnc(N)nc1N)c1)cc(OC)c1S(C)(=O)=O ZGDYNXRQVWHHOF-UHFFFAOYSA-N 0.000 description 1
- KMRNEFKOGMYHFM-UHFFFAOYSA-N CCc(cc(cc1)OC)c1Sc1cnc(N)nc1N Chemical compound CCc(cc(cc1)OC)c1Sc1cnc(N)nc1N KMRNEFKOGMYHFM-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/14—Antitussive agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
- C07D239/48—Two nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
- C07D239/50—Three nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pulmonology (AREA)
- Engineering & Computer Science (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662313334P | 2016-03-25 | 2016-03-25 | |
| US62/313,334 | 2016-03-25 | ||
| PCT/US2017/023126 WO2017165255A1 (en) | 2016-03-25 | 2017-03-20 | Pyrimidines and variants thereof, and uses therefor |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2019510025A JP2019510025A (ja) | 2019-04-11 |
| JP2019510025A5 JP2019510025A5 (cg-RX-API-DMAC7.html) | 2020-04-09 |
| JP6902045B2 true JP6902045B2 (ja) | 2021-07-14 |
Family
ID=59900805
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018549444A Active JP6902045B2 (ja) | 2016-03-25 | 2017-03-20 | ピリミジンおよびそのバリアント、ならびにそのための使用 |
Country Status (11)
| Country | Link |
|---|---|
| US (2) | US10662162B2 (cg-RX-API-DMAC7.html) |
| EP (1) | EP3433258B1 (cg-RX-API-DMAC7.html) |
| JP (1) | JP6902045B2 (cg-RX-API-DMAC7.html) |
| KR (1) | KR102377805B1 (cg-RX-API-DMAC7.html) |
| CN (1) | CN108779119B (cg-RX-API-DMAC7.html) |
| AU (1) | AU2017237929B2 (cg-RX-API-DMAC7.html) |
| CA (1) | CA3018180C (cg-RX-API-DMAC7.html) |
| MA (1) | MA44489A (cg-RX-API-DMAC7.html) |
| MX (1) | MX384368B (cg-RX-API-DMAC7.html) |
| RU (1) | RU2760733C2 (cg-RX-API-DMAC7.html) |
| WO (1) | WO2017165255A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10822311B2 (en) | 2016-03-14 | 2020-11-03 | Afferent Pharmaceuticals, Inc. | Pyrimidines and variants thereof, and uses therefor |
| KR102377805B1 (ko) | 2016-03-25 | 2022-03-22 | 애퍼런트 파마슈티컬스 인크. | 피리미딘 및 그의 변이체, 및 그의 용도 |
| AU2017381739B2 (en) | 2016-12-19 | 2020-06-11 | Novartis Ag | New picolinic acid derivatives and their use as intermediates |
| US10676444B2 (en) * | 2016-12-20 | 2020-06-09 | Afferent Pharmaceuticals, Inc. | Crystalline salts and polymorphs of a P2X3 antagonist |
| US11414444B2 (en) | 2017-11-01 | 2022-08-16 | Beijing Tide Pharmaceutical Co., Ltd. | P2X3 and/or P2X2/3 receptor antagonist, pharmaceutical composition comprising same, and use thereof |
| CN107778255B (zh) * | 2017-11-16 | 2019-10-25 | 山东大学 | 一种二芳基嘧啶类hiv-1逆转录酶抑制剂及其制备方法和应用 |
| KR20220008286A (ko) * | 2019-04-30 | 2022-01-20 | 베이징 타이드 파마슈티컬 코퍼레이션 리미티드 | 디아미노피리미딘 화합물을 사용하여 자궁내막증-관련 통증 치료 방법 |
| WO2020221275A1 (zh) * | 2019-04-30 | 2020-11-05 | 北京泰德制药股份有限公司 | 二氨基嘧啶类化合物或其水合物的固体形式及其制备方法和用途 |
| US20220211703A1 (en) * | 2019-04-30 | 2022-07-07 | Beijing Tide Pharmaceutical Co., Ltd. | Method for treating cough by using diaminopyrimidine compound |
| EP3981765A4 (en) * | 2019-06-06 | 2023-05-31 | Beijing Tide Pharmaceutical Co., Ltd. | P2X3 AND/OR P2X2/3 RECEPTOR ANTAGONIST, PHARMACEUTICAL COMPOSITION CONTAINING IT AND THEIR USE |
| CN120058573B (zh) * | 2025-04-29 | 2025-12-23 | 潍坊学院 | 一种1-三溴甲基磺酰基萘及其衍生物的合成方法 |
Family Cites Families (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US2953567A (en) * | 1956-11-23 | 1960-09-20 | Burroughs Wellcome Co | 5-phenylmercaptopyrimidines and method |
| WO2000059893A1 (en) * | 1999-04-06 | 2000-10-12 | Krenitsky Pharmaceuticals Inc. | Neurotrophic thio substituted pyrimidines |
| EP1345926B1 (en) | 2000-12-21 | 2006-05-17 | Vertex Pharmaceuticals Incorporated | Pyrazole compounds useful as protein kinase inhibitors |
| AU2005229331B2 (en) * | 2004-03-05 | 2011-10-13 | F. Hoffmann-La Roche Ag | Diaminopyrimidines as P2X3 and P2X2/3 antagonists |
| WO2007025899A1 (en) * | 2005-09-01 | 2007-03-08 | F. Hoffmann-La Roche Ag | Diaminopyrimidines as p2x3 and p2x2/3 modulators |
| EP1924566B1 (en) * | 2005-09-01 | 2016-01-13 | F.Hoffmann-La Roche Ag | Diaminopyrimidines as p2x3 and p2x2/3 modulators |
| BRPI0615040A2 (pt) * | 2005-09-01 | 2011-04-26 | Hoffmann La Roche | diaminopirimidinas como moduladores de p2x3 e p2x2/3 |
| EP1924565B1 (en) * | 2005-09-01 | 2016-09-14 | F.Hoffmann-La Roche Ag | Diaminopyrimidines as p2x3 and p3x2/3 modulators |
| EP2079713B1 (en) * | 2006-10-04 | 2014-04-16 | F. Hoffmann-La Roche AG | Process for synthesis of phenoxy diaminopyrimidine derivatives |
| WO2008104474A1 (en) * | 2007-02-28 | 2008-09-04 | F. Hoffmann-La Roche Ag | Diaminopyrimidines |
| WO2008104472A1 (en) | 2007-02-28 | 2008-09-04 | F. Hoffmann-La Roche Ag | 2, 4 -diaminopyrimidine derivatives and their use as p2x antagonists or as prodrugs thereof |
| AU2008319735A1 (en) * | 2007-10-31 | 2009-05-07 | Nissan Chemical Industries, Ltd. | Pyridazinone derivatives and use thereof as P2X7 receptor inhibitors |
| GB2471713A (en) | 2009-07-08 | 2011-01-12 | Univ Greenwich | 1,2,4-triazine derivatives and their use as sodium channel blockers |
| TWI637949B (zh) * | 2013-06-14 | 2018-10-11 | 塩野義製藥股份有限公司 | 胺基三衍生物及含有其等之醫藥組合物 |
| NZ716977A (en) * | 2013-08-23 | 2017-09-29 | Afferent Pharmaceuticals Inc | Methods of using diaminopyrimidine p2x3 and p2x2/3 receptor modulators for treatment of acute and sub-acute cough, urge to cough and chronic cough, in respiratory diseases |
| EP3981406A1 (en) * | 2014-07-03 | 2022-04-13 | Afferent Pharmaceuticals Inc. | Methods and compositions for treating diseases and conditions |
| US10822311B2 (en) * | 2016-03-14 | 2020-11-03 | Afferent Pharmaceuticals, Inc. | Pyrimidines and variants thereof, and uses therefor |
| KR102377805B1 (ko) * | 2016-03-25 | 2022-03-22 | 애퍼런트 파마슈티컬스 인크. | 피리미딘 및 그의 변이체, 및 그의 용도 |
-
2017
- 2017-03-20 KR KR1020187029805A patent/KR102377805B1/ko active Active
- 2017-03-20 RU RU2018137032A patent/RU2760733C2/ru active
- 2017-03-20 CN CN201780019534.0A patent/CN108779119B/zh active Active
- 2017-03-20 AU AU2017237929A patent/AU2017237929B2/en active Active
- 2017-03-20 EP EP17770880.7A patent/EP3433258B1/en active Active
- 2017-03-20 US US16/080,840 patent/US10662162B2/en active Active
- 2017-03-20 MA MA044489A patent/MA44489A/fr unknown
- 2017-03-20 WO PCT/US2017/023126 patent/WO2017165255A1/en not_active Ceased
- 2017-03-20 MX MX2018011622A patent/MX384368B/es unknown
- 2017-03-20 CA CA3018180A patent/CA3018180C/en active Active
- 2017-03-20 JP JP2018549444A patent/JP6902045B2/ja active Active
-
2020
- 2020-04-13 US US16/846,452 patent/US11230532B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| RU2760733C2 (ru) | 2021-11-30 |
| MA44489A (fr) | 2019-01-30 |
| CN108779119B (zh) | 2022-02-08 |
| US20200239421A1 (en) | 2020-07-30 |
| MX2018011622A (es) | 2019-03-28 |
| US10662162B2 (en) | 2020-05-26 |
| US20190055202A1 (en) | 2019-02-21 |
| MX384368B (es) | 2025-03-14 |
| CA3018180C (en) | 2024-02-20 |
| EP3433258B1 (en) | 2023-07-19 |
| AU2017237929B2 (en) | 2021-04-15 |
| AU2017237929A1 (en) | 2018-09-13 |
| KR102377805B1 (ko) | 2022-03-22 |
| JP2019510025A (ja) | 2019-04-11 |
| EP3433258A4 (en) | 2019-10-30 |
| RU2018137032A3 (cg-RX-API-DMAC7.html) | 2020-05-22 |
| EP3433258A1 (en) | 2019-01-30 |
| WO2017165255A1 (en) | 2017-09-28 |
| RU2018137032A (ru) | 2020-04-27 |
| CA3018180A1 (en) | 2017-09-28 |
| KR20180128015A (ko) | 2018-11-30 |
| BR112018069105A2 (pt) | 2019-01-29 |
| US11230532B2 (en) | 2022-01-25 |
| CN108779119A (zh) | 2018-11-09 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP6902045B2 (ja) | ピリミジンおよびそのバリアント、ならびにそのための使用 | |
| JP6968810B2 (ja) | ピリミジンおよびそのバリアント、ならびにそのための使用 | |
| EP2183224B1 (en) | 6-amino-pyrimidine-4-carboxamide derivatives and related compounds which bind to the sphingosine 1-phosphate (s1p) receptor for the treatment of multiple sclerosis | |
| US9227951B2 (en) | Substituted hydroxamic acids and uses thereof | |
| KR20150128722A (ko) | 카텝신 c의 억제제로서 치환된 2-아자-바이사이클로[2.2.1]헵탄-3-카복실산(벤질-시아노-메틸)-아미드 | |
| JP6180643B2 (ja) | 新規フタラジノン誘導体及びその製造方法「Ａ ｎｏｖｅｌ ｐｈｔａｌａｚｉｎｏｎｅ ｄｅｒｉｖａｔｉｖｅｓ ａｎｄ ｍａｎｕｆａｃｔｕｒｉｎｇ ｐｒｏｃｅｓｓ ｔｈｅｒｅｏｆ」 | |
| TW200819439A (en) | 2-amino-5-substituted pyrimidine inhibitors | |
| CZ20033431A3 (en) | 5-ht receptor ligands and uses thereof | |
| TW201211007A (en) | Substituted 2-amino-quinoline-3-carboxamides as KCNQ2/3 modulators | |
| CN104684899A (zh) | 取代的磺酰胺化合物 | |
| WO2018113694A1 (zh) | 稠环基氮杂环丁基三唑类衍生物、其制备方法及其在医药上的应用 | |
| US6030975A (en) | Carboxylic acid derivatives, their preparation and use in treating cancer | |
| JP7634083B2 (ja) | 新規なピラゾール誘導体 | |
| CN116710442A (zh) | 治疗病症的化合物、组合物和方法 | |
| TW201726651A (zh) | ２，３，４，５－四氫吡啶－６－胺衍生物 | |
| CN118742539A (zh) | 杂环类衍生物及其制备方法和用途 | |
| JP2004099598A (ja) | 新規なイソオキサゾール−スルホンアミドエンドセリンアンタゴニスト | |
| CN106749203A (zh) | 一种嘧啶类杂环化合物、嘧啶类杂环化合物盐以及制备方法和应用 | |
| BR112018069105B1 (pt) | Composto de pirimidina, composição e uso do mesmo | |
| TW200403063A (en) | Novel compounds | |
| HK1230168B (zh) | 经取代的双环二氢嘧啶酮及其作为嗜中性粒细胞弹性蛋白酶活性的抑制剂的用途 | |
| HK1230167B (zh) | 经取代的双环二氢嘧啶酮及其作为嗜中性粒细胞弹性蛋白酶活性的抑制剂的用途 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20181121 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20200228 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20200228 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A132 Effective date: 20210105 |
|
| A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20201224 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20210401 |
|
| TRDD | Decision of grant or rejection written | ||
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20210525 |
|
| A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20210618 |
|
| R150 | Certificate of patent or registration of utility model |
Ref document number: 6902045 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
| S531 | Written request for registration of change of domicile |
Free format text: JAPANESE INTERMEDIATE CODE: R313531 |
|
| R350 | Written notification of registration of transfer |
Free format text: JAPANESE INTERMEDIATE CODE: R350 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |